Shares of DOR BioPharma soared on Friday afternoon after the company announced it had received an unsolicited buyout offer from Cell Therapeutics. CTI offered to issue 29 million shares to complete the deal, valuing the offer at $50 million. DOR, though, says it has to resolve a letter of intent on a partnership deal for its lead program with Sigma-Tau Pharmaceuticals before it can consider the offer. Press release | Report